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Conclusions: Severe HSRs necessitated enrollment suspension at se-
lect southeastern U.S. sites where a higher than expected HSR rate was 
observed. However, this trial continues to accrue at other network sites. 
Additional follow-up is needed to better assess the role of cetuximab 
with this non-platinum regimen in NSCLC.
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Background: Somatically acquired mutations in the EGFR gene in 
non-small cell lung cancer (NSCLC) are associated with a signiﬁcant 
clinical response to tyrosine kinase inhibitor (TKI), such as geﬁtinib 
or erlotinib. In our retrospective study, cases with EGFR mutations 
(exon19 deletion or exon21 L858R) showed a high sensitivity to 
geﬁtinib, and the patients with sensitive EGFR mutations also tended 
to have a more favorable prognosis than those with wild-type after ge-
ﬁtinib treatment (Lung Cancer 2006;51:71, Br J Cancer 2006;94:896). 
However, most patients with such sensitive mutations in their tumor 
show progression during the TKI treatment. In such resistant tumors, a 
secondary mutation at codon 790 (T790M) in exon20 has been reported 
to be related the resistance to either geﬁtinib or erlotinib.
Methods: Patients with either recurrent disease after undergoing sur-
gery or advanced disease (IIIB or IV) of NSCLC which demonstrated 
EGFR mutations were eligible for the prospective study of treatment 
with geﬁtinib. EGFR mutations in exons 19-21 were examined by our 
previously described screening method and conﬁrmed by direct se-
quencing, and 18 patients were enrolled in this trial whose pretreatment 
tumors had EGFR mutations (11 males and 7 females), after informed 
consent was obtained. Seven patients had a deletion in exon 19, 9 had a 
missense mutation in exon 21 (L858R), 1 had both an exon 19 del and 
L858R, and 1 had an exon19 del and G796A in exon20 (Case 1). Of the 
18 cases, 9 showed PR, 7 showed SD and 2 showed PD. The response 
rate was 50% and disease-control rate was 89%. Of the 9 patients 
with PR, 2 tumor samples (Case 2: lung, Case 3: pleural effusion) that 
became refractory to geﬁtinib were obtained.
Results: Case 1 (71 years-old female): Pretreatment tumor sample 
demonstrated the co-existence of an in-frame deletion in exon19 and 
a missense mutation (G796A) in exon20. In vitro, a stable clone of 
cells bearing the G796A mutation was approximately 50,000-fold less 
sensitive to geﬁtinib in comparison to the cells carrying exon19 dele-
tion. Case 2 (55 years-old male): Pretreatment tumor sample (primary 
lung lesion) had an in-frame deletion in exon19 (del E746-A750). 
Four metastatic lung lesions that became refractory to geﬁtinib were 
obtained, and one of 4 showed a secondary T790M mutation in exon20, 
which was not detected in the pretreatment tumor samples. Case 3 (65 
years-old female): Pretreatment tumor sample (metastatic subclavicu-
lar lymph node) had an in-frame deletion in exon19 (del E746-A750). 
Pleural ﬂuid that became refractory to geﬁtinib was obtained, and the 
sample showed a secondary T790M mutation in exon20. 
Conclusions: Our results suggest that T790M and G796A mutations 
in exon20 are useful biomarker for acquired and primary resistance 
to TKI (geﬁtinib). Because all refractory tumors do not always have 
T790M mutation, other mechanism in addition to T790M might play a 
role in the acquisition of resistant to geﬁtinib.
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Purpose: Recently, somatic mutations in Epidermal Growth Factor Re-
ceptor (EGFR) exon 18-21 have been identiﬁed in non-small cell lung 
carcinomas that predict response to Tyrosine Kinase Inhibitors (TKI), 
but only exon 19 deletions predict survival. As the direct sequencing 
is time consuming and can be technically difﬁcult and costly, we have 
developed a simple, PCR-based method to detect exon 19 deletion mu-
tations as a potentially cost effective and sensitive method for identify-
ing those NSCLC patients for whom TKI treatment may offer survival 
beneﬁt.
Materials and Methods: A total of 9 NSCLC lines and 73 clinical 
tumor samples from Japanese patients which were treated with geﬁtinib 
were tested in this study. Five cell lines (HCC827, H1650, HCC2279, 
HCC4006 and H3255) have known mutations in EGFR TK domain, 
and 4 cell lines (H157, H460, H520 and A549) have no known muta-
tions and are resistant to geﬁtinib. Formalin Fixed Parafﬁn Embedded 
(FFPE) sections from clinical samples and cytology preparations were 
microdissected under stereoscopic microscopy. A semi-nested PCR was 
employed to amplify exon 19 in which the ﬁrst round primers were 
placed in the introns encompassing the whole of exon 19. Template 
from the ﬁrst round PCR was ampliﬁed with two additional primer sets 
(the screening PCR and delE746_A750 speciﬁc PCR). The screening 
PCR primers encompass all known exon 19 deletions and delE746_
A750 speciﬁc PCR primers were designed to skip delE746-750A. 
Results: Successful detection of known mutations was achieved in 
HCC827 and HCC2279 with as little as 40 picograms of puriﬁed DNA 
and at mutant to wild type DNA ratios (M/W) of 1/600. DNA from a 
single cell from a cytology preparation could be ampliﬁed by this assay. 
The assay detected variations in the M/W ratio even in cell lines with 
deletion. All deletions present in cell lines and none of the non-mutant 
lines were positive by this assay (100% sensitivity and speciﬁcity). 
In 73 clinical cases, the assay detected deletion mutations in 25 cases 
(34.2%). Five of 25 cases were not detected by sequencing and this 
assay thus was more sensitive in clinical samples than sequencing. Log 
rank analysis indicated signiﬁcant survival difference between patients 
with and without exon 19 deletion (p=0.017).
Conclusions: PCR-based EGFR exon 19 deletion assay is sensitive 
for all known mutations in exon 19. It can be performed on parafﬁn 
embedded tissue and cytology samples rapidly and may be suitable for 
economical large scale screening in clinical samples. 
